Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Ascentage Reports 95% Complete Response of BCR-ABL Inhibitor in Leukemia Patients

publication date: Dec 12, 2019

Suzhou Ascentage Pharma reported a 95% complete hematologic response rate in one cohort in a China Phase I trial of its BCR-ABL Tyrosine Kinase Inhibitor in TKI-resistant patients with chronic myeloid leukemia. Ascentage describes HQP1351 as a novel oral third-generation BCR-ABL inhibitor that targets a broad spectrum of BCR-ABL mutants, including the T315I mutation, to treat drug-resistant CML patients. Ascentage has three pivotal China Phase II clinical trials of HQP1351 underway in China. More details...

Stock Symbol: (HK: 6855)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.